metformin has been researched along with Albuminuria in 47 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of his study was to compare the efficacy of pioglitazone with metformin on the reduction of albuminuria in type 2 diabetic patients with hypertension and microalbuminuria treated with renin-angiotensin system inhibitors (RAS-Is)." | 9.15 | Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. ( Haneda, M; Ishizeki, K; Itoh, H; Iwashima, Y; Miura, T; Morikawa, A; Muto, E; Oshima, E; Sekiguchi, M; Yokoyama, H, 2011) |
| "To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control." | 9.12 | Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. ( Bakris, GL; Freed, MI; Heise, MA; McMorn, SO; Porter, LE; Ruilope, LM; Weston, WM, 2006) |
| "Troglitazone ameliorated microalbuminuria in diabetic nephropathy." | 9.08 | Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. ( Arai, K; Hori, M; Imano, E; Kajimoto, Y; Kanda, T; Motomura, M; Nakatani, Y; Nishida, T; Yamasaki, Y, 1998) |
| "A total of 26 non-insulin-dependent diabetic patients were enrolled for a clinical study of the effect of buflomedil on microalbuminuria." | 9.07 | The effect of oral buflomedil on microalbuminuria in non-insulin-dependent diabetic patients. ( Chuang, LM; Lin, BJ; Tai, TY; Tseng, CH; Wu, HP, 1992) |
| "These findings indicate that metformin treatment improves glycemic control, and lowers insulin resistance and risk factors for cardiovascular disease, including PAI-1, and may therefore be useful in the long-term management of NIDDM subjects who have a high risk of cardiovascular disease." | 9.07 | Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. ( Nagi, DK; Yudkin, JS, 1993) |
| "Metformin was added progressively over a year in total doses of 1." | 6.69 | [The combination of insulin and metformin in obese patients with type-2 diabetes mellitus]. ( Ibarra Rueda, JM; Ruiz de Adana Pérez, R; Sánchez-Barba Izquierdo, MI, 1999) |
| "Metformin has been the most prescribed glucose-lowering medicine worldwide, and its potential for many other therapeutic applications is also being explored intensively." | 5.48 | Metformin attenuates folic-acid induced renal fibrosis in mice. ( Cao, Q; Chen, J; Chen, XM; Huang, C; Pollock, CA; Shi, Y; Yi, H; Zhang, L; Zhao, Y, 2018) |
| " Secondary goals examined albuminuria, age, race, sex, and metformin prescription." | 5.20 | Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. ( Poretsky, L; Striker, GE; Vlassara, H; Woodward, M; Yubero-Serrano, EM, 2015) |
| "The aim of his study was to compare the efficacy of pioglitazone with metformin on the reduction of albuminuria in type 2 diabetic patients with hypertension and microalbuminuria treated with renin-angiotensin system inhibitors (RAS-Is)." | 5.15 | Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. ( Haneda, M; Ishizeki, K; Itoh, H; Iwashima, Y; Miura, T; Morikawa, A; Muto, E; Oshima, E; Sekiguchi, M; Yokoyama, H, 2011) |
| "To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control." | 5.12 | Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. ( Bakris, GL; Freed, MI; Heise, MA; McMorn, SO; Porter, LE; Ruilope, LM; Weston, WM, 2006) |
| " Twenty-seven patients (26 male, 1 female, aged 48-68 years) with T2DM and microalbuminuria were treated with folic acid 10 mg daily for 3 months." | 5.11 | The effect of oral folic acid on glutathione, glycaemia and lipids in Type 2 diabetes. ( Brain, AM; Child, DF; Davies, GK; De, P; Harvey, JN; Hudson, PR; Jones, H; Mukherjee, S; Williams, CP, 2004) |
| "Combination therapy with bedtime insulin plus metformin prevents weight gain." | 5.09 | Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. ( Heikkilä, M; Nikkilä, K; Ryysy, L; Tulokas, T; Vanamo, R; Yki-Järvinen, H, 1999) |
| "Troglitazone ameliorated microalbuminuria in diabetic nephropathy." | 5.08 | Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. ( Arai, K; Hori, M; Imano, E; Kajimoto, Y; Kanda, T; Motomura, M; Nakatani, Y; Nishida, T; Yamasaki, Y, 1998) |
| "These findings indicate that metformin treatment improves glycemic control, and lowers insulin resistance and risk factors for cardiovascular disease, including PAI-1, and may therefore be useful in the long-term management of NIDDM subjects who have a high risk of cardiovascular disease." | 5.07 | Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. ( Nagi, DK; Yudkin, JS, 1993) |
| "A total of 26 non-insulin-dependent diabetic patients were enrolled for a clinical study of the effect of buflomedil on microalbuminuria." | 5.07 | The effect of oral buflomedil on microalbuminuria in non-insulin-dependent diabetic patients. ( Chuang, LM; Lin, BJ; Tai, TY; Tseng, CH; Wu, HP, 1992) |
| " Metformin and renin-angiotensin system blockers were negatively associated with albuminuria and chronic kidney disease stages (p < 0." | 4.02 | Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study. ( Abdulraheem, AM; Abufaraj, M; Al-Sabbagh, MQ; Albtoosh, A; Aljabiri, H; Arabiat, M; Farah, RI; Momani, MS, 2021) |
| "Metformin, an AMP-activated protein kinase (AMPK) activator, has been shown in previous studies to reduce kidney fibrosis in different models of experimental chronic kidney disease (CKD)." | 3.96 | Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease. ( Borges, CM; de Ávila, VF; Formigari, GP; Fujihara, CK; Lopes de Faria, JB; Malheiros, DMAC, 2020) |
| "Mean composite kidney disease progression occurred in 135 (10." | 3.30 | Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial. ( Bebu, I; de Boer, IH; Ghosh, A; Inzucchi, SE; Ismail-Beigi, F; McGill, JB; Mudaliar, S; Schade, D; Steffes, MW; Tamborlane, WV; Tan, MH; Wexler, DJ; Younes, N, 2023) |
| "In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups." | 3.11 | Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. ( Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N, 2022) |
| "People with insulin-requiring type 2 diabetes and high cardiovascular risk were enrolled during a run-in period on basal-bolus insulin (BBI), and 102 were randomized to continued BBI or to basal insulin with a prandial GLP-1 receptor agonist (GLIPULIN) group, each seeking to maintain HbA(1c) levels between 6." | 2.80 | Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. ( Bergenstal, R; Branch, KR; Davis, B; Hirsch, I; Khakpour, D; Kingry, C; O'Brien, K; Pressel, S; Probstfield, JL; Riddle, M, 2015) |
| " The overall frequency of adverse events was similar between treatment groups, but adverse event profiles were different between treatment groups." | 2.71 | Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. ( Brunetti, P; Charbonnel, B; Hanefeld, M; Matthews, DR; Schernthaner, G, 2004) |
| "In patients with type 2 diabetes treated with insulin, metformin treatment was associated with improvement of endothelial function, which was largely unrelated to changes in glycaemic control, but not with improvement of chronic, low-grade inflammation." | 2.71 | Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. ( Bets, D; De Jager, J; Donker, AJ; Kooy, A; Lehert, P; Schalkwijk, CG; Scheffer, PG; Stehouwer, CD; Teerlink, T; Wulffelé, MG, 2005) |
| "Metformin was added progressively over a year in total doses of 1." | 2.69 | [The combination of insulin and metformin in obese patients with type-2 diabetes mellitus]. ( Ibarra Rueda, JM; Ruiz de Adana Pérez, R; Sánchez-Barba Izquierdo, MI, 1999) |
| "Thirty-nine mildly obese NIDDM patients (BMI 25." | 2.68 | Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. ( Clauson, P; Efendic, S; Karlander, S; Steen, L, 1996) |
| "Type 2 diabetes mellitus is a troubling chronic disease and diabetic nephropathy is one of the most important complications of diabetes mellitus." | 2.49 | Bright renoprotective properties of metformin: beyond blood glucose regulatory effects. ( Ardalan, MR; Baradaran, A; Mardani, S; Momeni, A; Nasri, H; Rafieian-Kopaei, M, 2013) |
| "Patients with type 2 diabetes have an increased risk for cardiovascular disease (CVD) and it accounts for up to 80% of excess deaths in these patients." | 2.42 | Role of oral anti-diabetic agents in modifying cardiovascular risk factors. ( Farag, A; McFarlane, SI; Rothman, J; Shin, JJ; Sowers, JR, 2003) |
| "Type 2 diabetes is strongly associated with increased risk of cardiovascular disease." | 2.42 | Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. ( Evans, M; Rees, A; Roberts, AW; Thomas, A, 2003) |
| "In the treatment of type 2 diabetes, evidence of the comparative effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas-the second most widely used antihyperglycemic class after metformin-is lacking." | 1.62 | Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. ( Al-Aly, Z; Bowe, B; Gibson, AK; Maddukuri, G; McGill, JB; Xie, Y, 2021) |
| "Diabetic nephropathy is one of the most common and serious complications of diabetes mellitus." | 1.48 | Ameliorative effects of protodioscin on experimental diabetic nephropathy. ( Dong, Y; Guo, C; Liu, Y; Xie, G; Zhu, H, 2018) |
| "Metformin has been the most prescribed glucose-lowering medicine worldwide, and its potential for many other therapeutic applications is also being explored intensively." | 1.48 | Metformin attenuates folic-acid induced renal fibrosis in mice. ( Cao, Q; Chen, J; Chen, XM; Huang, C; Pollock, CA; Shi, Y; Yi, H; Zhang, L; Zhao, Y, 2018) |
| "Metformin treatment of T2DM rats produced dose-dependent significant reductions in urinary albumin and nephrin concentrations, glomerular basement membrane thickness (GBMT), and the foot process fusion rate (FPFR) compared with control T2DM model rats, whereas renal expression of nephrin protein and Nphs1 mRNA was dose-dependently increased by metformin treatment." | 1.46 | Metformin ameliorates podocyte damage by restoring renal tissue nephrin expression in type 2 diabetic rats. ( Gu, J; Hu, W; Wang, W; Yang, D; Ye, S; Zhai, L, 2017) |
| "Metformin treatment was effective in lowering hyperglycemia only during the first 2 weeks of treatment." | 1.40 | Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice. ( Boivin, GP; Elased, KM; Somineni, HK, 2014) |
| "Metformin was independently associated with lower prevalence of cardiovascular disease for any age quartile and eGFR category than all other treatments." | 1.39 | Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. ( Bonora, E; Cavalot, F; Cignarelli, M; Ferrannini, E; Fondelli, C; Morano, S; Orsi, E; Penno, G; Pugliese, G; Solini, A; Trevisan, R; Vedovato, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (12.77) | 18.2507 |
| 2000's | 12 (25.53) | 29.6817 |
| 2010's | 22 (46.81) | 24.3611 |
| 2020's | 7 (14.89) | 2.80 |
| Authors | Studies |
|---|---|
| Nathan, DM | 1 |
| Lachin, JM | 3 |
| Bebu, I | 2 |
| Burch, HB | 1 |
| Buse, JB | 1 |
| Cherrington, AL | 1 |
| Fortmann, SP | 1 |
| Green, JB | 1 |
| Kahn, SE | 3 |
| Kirkman, MS | 1 |
| Krause-Steinrauf, H | 1 |
| Larkin, ME | 1 |
| Phillips, LS | 1 |
| Pop-Busui, R | 1 |
| Steffes, M | 1 |
| Tiktin, M | 1 |
| Tripputi, M | 1 |
| Wexler, DJ | 2 |
| Younes, N | 2 |
| Mannucci, E | 1 |
| Gallo, M | 1 |
| Giaccari, A | 1 |
| Candido, R | 1 |
| Pintaudi, B | 1 |
| Targher, G | 1 |
| Monami, M | 1 |
| de Boer, IH | 1 |
| Ghosh, A | 1 |
| Inzucchi, SE | 1 |
| McGill, JB | 2 |
| Mudaliar, S | 1 |
| Schade, D | 1 |
| Steffes, MW | 1 |
| Tamborlane, WV | 1 |
| Tan, MH | 1 |
| Ismail-Beigi, F | 1 |
| Borges, CM | 1 |
| Fujihara, CK | 1 |
| Malheiros, DMAC | 1 |
| de Ávila, VF | 1 |
| Formigari, GP | 1 |
| Lopes de Faria, JB | 1 |
| Mostafa, DK | 1 |
| Khedr, MM | 1 |
| Barakat, MK | 1 |
| Abdellatif, AA | 1 |
| Elsharkawy, AM | 1 |
| Farah, RI | 1 |
| Al-Sabbagh, MQ | 1 |
| Momani, MS | 1 |
| Albtoosh, A | 1 |
| Arabiat, M | 1 |
| Abdulraheem, AM | 1 |
| Aljabiri, H | 1 |
| Abufaraj, M | 1 |
| Xie, Y | 1 |
| Bowe, B | 1 |
| Gibson, AK | 1 |
| Maddukuri, G | 1 |
| Al-Aly, Z | 1 |
| Yi, H | 1 |
| Huang, C | 1 |
| Shi, Y | 1 |
| Cao, Q | 1 |
| Zhao, Y | 1 |
| Zhang, L | 1 |
| Chen, J | 1 |
| Pollock, CA | 1 |
| Chen, XM | 1 |
| Lim, S | 1 |
| Eckel, RH | 1 |
| Koh, KK | 1 |
| Guo, C | 1 |
| Dong, Y | 1 |
| Zhu, H | 1 |
| Liu, Y | 1 |
| Xie, G | 1 |
| Pan, Q | 3 |
| Xu, Y | 2 |
| Yang, N | 2 |
| Gao, X | 2 |
| Liu, J | 2 |
| Yang, W | 2 |
| Wang, G | 2 |
| Kidokoro, K | 1 |
| Satoh, M | 1 |
| Channon, KM | 1 |
| Yada, T | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Solini, A | 1 |
| Penno, G | 1 |
| Bonora, E | 1 |
| Fondelli, C | 1 |
| Orsi, E | 1 |
| Trevisan, R | 1 |
| Vedovato, M | 1 |
| Cavalot, F | 1 |
| Cignarelli, M | 1 |
| Morano, S | 1 |
| Ferrannini, E | 1 |
| Pugliese, G | 1 |
| Nasri, H | 1 |
| Baradaran, A | 1 |
| Ardalan, MR | 1 |
| Mardani, S | 1 |
| Momeni, A | 1 |
| Rafieian-Kopaei, M | 1 |
| Somineni, HK | 1 |
| Boivin, GP | 1 |
| Elased, KM | 1 |
| Yubero-Serrano, EM | 1 |
| Woodward, M | 1 |
| Poretsky, L | 1 |
| Vlassara, H | 1 |
| Striker, GE | 1 |
| Alamdari, A | 1 |
| Mozafari, R | 1 |
| Tafakhori, A | 1 |
| Faghihi-Kashani, S | 1 |
| Hafezi-Nejad, N | 1 |
| Sheikhbahaei, S | 1 |
| Naderi, N | 1 |
| Ebadi, M | 1 |
| Esteghamati, A | 1 |
| Regelmann, MO | 1 |
| Goldis, M | 1 |
| Arnon, R | 1 |
| Probstfield, JL | 1 |
| Hirsch, I | 1 |
| O'Brien, K | 1 |
| Davis, B | 1 |
| Bergenstal, R | 1 |
| Kingry, C | 1 |
| Khakpour, D | 1 |
| Pressel, S | 1 |
| Branch, KR | 1 |
| Riddle, M | 1 |
| Mather, KJ | 1 |
| Knowler, WC | 1 |
| Funahashi, T | 1 |
| Bray, GA | 1 |
| Arakaki, R | 1 |
| Falkner, B | 1 |
| Sharma, K | 1 |
| Goldstein, BJ | 1 |
| Zhai, L | 1 |
| Gu, J | 1 |
| Yang, D | 1 |
| Hu, W | 1 |
| Wang, W | 1 |
| Ye, S | 1 |
| Chen, YH | 1 |
| Tarng, DC | 1 |
| Chen, HS | 1 |
| Viberti, G | 2 |
| Zinman, B | 2 |
| Haffner, SM | 2 |
| Aftring, RP | 1 |
| Paul, G | 1 |
| Kravitz, BG | 1 |
| Herman, WH | 2 |
| Holman, RR | 2 |
| Crasto, W | 1 |
| Jarvis, J | 1 |
| Khunti, K | 1 |
| Skinner, TC | 1 |
| Gray, LJ | 1 |
| Brela, J | 1 |
| Troughton, J | 1 |
| Daly, H | 1 |
| Lawrence, IG | 1 |
| McNally, PG | 1 |
| Carey, ME | 1 |
| Davies, MJ | 1 |
| Morikawa, A | 1 |
| Ishizeki, K | 1 |
| Iwashima, Y | 1 |
| Yokoyama, H | 1 |
| Muto, E | 1 |
| Oshima, E | 1 |
| Sekiguchi, M | 1 |
| Miura, T | 1 |
| Itoh, H | 1 |
| Haneda, M | 1 |
| Gosmanova, EO | 1 |
| Canada, RB | 1 |
| Wan, J | 1 |
| Mangold, TA | 1 |
| Wall, BM | 1 |
| Kacso, IM | 1 |
| Bondor, CI | 1 |
| Kacso, G | 1 |
| Kim, J | 1 |
| Shon, E | 1 |
| Kim, CS | 1 |
| Kim, JS | 1 |
| Greene, DA | 1 |
| Levy, D | 1 |
| Berry, RA | 1 |
| Heise, MA | 2 |
| Jones, NP | 1 |
| Freed, MI | 2 |
| Serrano Rios, M | 1 |
| Ascaso Gimilio, JF | 1 |
| Blázquez Fernández, E | 1 |
| Cabezas Cerraro, J | 1 |
| Carmena Rodríguez, R | 1 |
| Escobar Jiménez, F | 1 |
| Fernández-Real, JM | 1 |
| Gabriel Sánchez, R | 1 |
| Gomis de Barberá, R | 1 |
| Grande Aragón, C | 1 |
| Herrera Pomba, JL | 1 |
| Pallardo Sánchez, LF | 1 |
| Potau Vilalta, N | 1 |
| Ricart Engel, W | 1 |
| Rovira Loscos, A | 1 |
| Zorzano Olarte, A | 1 |
| Roberts, AW | 1 |
| Thomas, A | 1 |
| Rees, A | 1 |
| Evans, M | 1 |
| Shin, JJ | 1 |
| Rothman, J | 1 |
| Farag, A | 1 |
| McFarlane, SI | 1 |
| Sowers, JR | 1 |
| Child, DF | 1 |
| Hudson, PR | 1 |
| Jones, H | 1 |
| Davies, GK | 1 |
| De, P | 1 |
| Mukherjee, S | 1 |
| Brain, AM | 1 |
| Williams, CP | 1 |
| Harvey, JN | 1 |
| Schernthaner, G | 1 |
| Matthews, DR | 1 |
| Charbonnel, B | 1 |
| Hanefeld, M | 1 |
| Brunetti, P | 1 |
| De Jager, J | 1 |
| Kooy, A | 1 |
| Lehert, P | 1 |
| Bets, D | 1 |
| Wulffelé, MG | 1 |
| Teerlink, T | 1 |
| Scheffer, PG | 1 |
| Schalkwijk, CG | 1 |
| Donker, AJ | 1 |
| Stehouwer, CD | 1 |
| Kadhim, HM | 1 |
| Ismail, SH | 1 |
| Hussein, KI | 1 |
| Bakir, IH | 1 |
| Sahib, AS | 1 |
| Khalaf, BH | 1 |
| Hussain, SA | 1 |
| Bakris, GL | 1 |
| Ruilope, LM | 1 |
| McMorn, SO | 1 |
| Weston, WM | 1 |
| Porter, LE | 1 |
| Cubeddu, LX | 1 |
| Alfieri, AB | 1 |
| Hoffmann, IS | 1 |
| Nagi, DK | 1 |
| Yudkin, JS | 1 |
| Clauson, P | 1 |
| Karlander, S | 1 |
| Steen, L | 1 |
| Efendic, S | 1 |
| Imano, E | 1 |
| Kanda, T | 1 |
| Nakatani, Y | 1 |
| Nishida, T | 1 |
| Arai, K | 1 |
| Motomura, M | 1 |
| Kajimoto, Y | 1 |
| Yamasaki, Y | 1 |
| Hori, M | 1 |
| Yki-Järvinen, H | 1 |
| Ryysy, L | 1 |
| Nikkilä, K | 1 |
| Tulokas, T | 1 |
| Vanamo, R | 1 |
| Heikkilä, M | 1 |
| Sánchez-Barba Izquierdo, MI | 1 |
| Ibarra Rueda, JM | 1 |
| Ruiz de Adana Pérez, R | 1 |
| Jungmann, E | 1 |
| Helling, T | 1 |
| Jungmann, G | 1 |
| Mertens, C | 1 |
| Snelting, U | 1 |
| Tseng, CH | 1 |
| Tai, TY | 1 |
| Wu, HP | 1 |
| Chuang, LM | 1 |
| Lin, BJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study[NCT01794143] | Phase 3 | 5,047 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4: a Protocol of a Randomized, Parallel, Controlled Trial[NCT03596749] | Phase 3 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy[NCT01175486] | Phase 4 | 200 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism[NCT03398356] | Phase 4 | 47 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
| Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin[NCT02026310] | 40 participants (Actual) | Interventional | 2014-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
ADMA- asymmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: before study start; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.51 | 0.52 | 0.50 |
| Group B | 0.57 | 0.55 | 0.52 |
arginine serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 112.18 | 107.72 | 104.72 |
| Group B | 111.72 | 97.69 | 103.76 |
serum concentration of the citrulline (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 21.73 | 25.95 | 26.93 |
| Group B | 28.08 | 27.01 | 29.77 |
DMA- dimethylamine, serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 1.71 | 1.63 | 1.62 |
| Group B | 2.07 | 1.89 | 1.84 |
the serum concentration of the studied drug-metformin (NCT03398356)
Timeframe: 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 4.36 | 5.09 | 4.66 |
| Group B | 4.25 | 7.42 | 4.01 |
SDMA-symmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.40 | 0.41 | 0.39 |
| Group B | 0.45 | 0.42 | 0.39 |
6 reviews available for metformin and Albuminuria
| Article | Year |
|---|---|
Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta-analysis of randomized controlled trials with external adjudication of events.
Topics: Adult; Albuminuria; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Glucagon-Like Pe | 2023 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Disea | 2018 |
Bright renoprotective properties of metformin: beyond blood glucose regulatory effects.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2013 |
New-onset diabetes mellitus after pediatric liver transplantation.
Topics: Albuminuria; Child; Cyclosporine; Diabetes Mellitus; Diabetic Retinopathy; Glucocorticoids; Humans; | 2015 |
Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions.
Topics: Albuminuria; Arteriosclerosis; Blood Pressure; C-Reactive Protein; Carotid Arteries; Coronary Resten | 2003 |
Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
Topics: Albuminuria; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hemostasis; | 2003 |
23 trials available for metformin and Albuminuria
| Article | Year |
|---|---|
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Co | 2022 |
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Disease Progression; Female; Glomerular Filtration Ra | 2023 |
Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.
Topics: Adiponectin; Age Factors; Aged; Albuminuria; Chelating Agents; Diabetes Mellitus, Type 2; Diabetic N | 2015 |
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
Topics: Albuminuria; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2015 |
Treatment-Induced Changes in Plasma Adiponectin Do Not Reduce Urinary Albumin Excretion in the Diabetes Prevention Program Cohort.
Topics: Adiponectin; Adult; Albuminuria; Creatinine; Cross-Sectional Studies; Diabetes Mellitus; Female; Hum | 2015 |
Comparison of Acarbose and Metformin on Albumin Excretion in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial.
Topics: Acarbose; Albuminuria; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metform | 2016 |
Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
Topics: Acarbose; Aged; Albumins; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Drug Th | 2016 |
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diab | 2011 |
Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Aspirin; Blood Pressure; Chole | 2011 |
Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2011 |
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Gly | 2002 |
The effect of oral folic acid on glutathione, glycaemia and lipids in Type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure; Cholesterol, HDL; Diabetes Mellitus, Type 2 | 2004 |
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; | 2004 |
Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type | 2005 |
Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin.
Topics: Adult; Albuminuria; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug | 2006 |
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Cohort Studies; Diabetes Mellitus, Type | 2006 |
Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese "normoalbuminuric" non-diabetic subjects.
Topics: Adult; Albuminuria; Blood Pressure; Caloric Restriction; Cardiovascular Diseases; Creatinine; Exerci | 2008 |
Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
Topics: Albuminuria; Asia; Biomarkers; Blood Glucose; C-Peptide; Cardiovascular Diseases; Cholesterol; Diabe | 1993 |
Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
Topics: Aged; Albuminuria; Analysis of Variance; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cho | 1996 |
Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Cholesterol; Cholesterol, HDL; Chromans | 1998 |
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.
Topics: Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Drug Administratio | 1999 |
[The combination of insulin and metformin in obese patients with type-2 diabetes mellitus].
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 1999 |
The effect of oral buflomedil on microalbuminuria in non-insulin-dependent diabetic patients.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; | 1992 |
18 other studies available for metformin and Albuminuria
| Article | Year |
|---|---|
Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Disease Progression; En | 2020 |
Autophagy blockade mechanistically links proton pump inhibitors to worsened diabetic nephropathy and aborts the renoprotection of metformin/enalapril.
Topics: Albuminuria; Animals; Autophagy; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diet, High | 2021 |
Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study.
Topics: Age Factors; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Cross-Sectional Studies; Diabete | 2021 |
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
Topics: Albuminuria; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; | 2021 |
Metformin attenuates folic-acid induced renal fibrosis in mice.
Topics: Albuminuria; Animals; Cell Line; Chemokine CCL2; Collagen Type IV; Disease Models, Animal; Extracell | 2018 |
Ameliorative effects of protodioscin on experimental diabetic nephropathy.
Topics: Albuminuria; Animals; Blood Glucose; Blood Urea Nitrogen; Carboxymethylcellulose Sodium; Cholesterol | 2018 |
Metformin or Acarbose Treatment Significantly Reduced Albuminuria in Patients with Newly Diagnosed Type 2 Diabetes Mellitus and Low-Grade Albuminuria.
Topics: Acarbose; Adult; Aged; Albuminuria; Blood Glucose; Body Mass Index; China; Diabetes Mellitus, Type 2 | 2018 |
Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.
Topics: Albuminuria; Animals; Biopterins; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies | 2013 |
Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
Topics: Age Factors; Aged; Albuminuria; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; | 2013 |
Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme 2; Animals; Combined Modality Therapy; Diabetes Complicat | 2014 |
An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects.
Topics: Adult; Albuminuria; Case-Control Studies; Diabetic Neuropathies; Female; Humans; Hypertension; Linea | 2015 |
Metformin ameliorates podocyte damage by restoring renal tissue nephrin expression in type 2 diabetic rats.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Die | 2017 |
Changes in albumin excretion in the diabetes prevention program.
Topics: Adult; Aged; Albuminuria; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Female; Humans; Hyp | 2009 |
Different antidiabetic regimens and the development of renal dysfunction in US Veterans with type 2 diabetes mellitus.
Topics: Albuminuria; Creatinine; Demography; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; | 2012 |
Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A.
Topics: Aged; Albuminuria; Biomarkers; Case-Control Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic | 2012 |
Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Animals; Antioxidants; Apoptosis; Deoxyguanosine; Diabetes | 2012 |
[Insulin resistance and its involvement in multiple risk factors associated with type 2 diabetes mellitus].
Topics: Adult; Albuminuria; Diabetes Mellitus, Type 2; Europe; Female; Humans; Hypercholesterolemia; Hyperli | 2002 |
[Intensified conventional insulin therapy in patients with type 2 diabetes mellitus. Positive long-term effects of insulin lispro on metabolic control and microalbuminuria].
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Dr | 2001 |